Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile
International Immunopharmacology · 2023-07 · 120 · 110368
DOI: 10.1016/j.intimp.2023.110368 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023-07. Verfasst von Tianbing Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Anhui No.2 Provincial People's Hospital, Hefei 230000, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 126-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Anhui Science and Technology Department.
Abstract (Originalsprache)
A new mode of cell death, disulfidptosis, has been discovered. Clinical prognostic significance of disulfidptosis related pattern in hepatocellular carcinoma(HCC). In this study, a risk score model was established based on disulfidptosis model to analyze the role of risk score in clinical prognosis, immune cell infiltration, drug sensitivity and immunotherapy response. Disulfidptosis subtype were constructed based on the transcriptional profiles of 15 disulfidptosis-related genes(DRGs). All 601 samples were defined as high risk group(HRG) and low risk group(LRG) based on the disulfidptosis risk score. Drug sensitivity and response to immunotherapy were calculated by immunophenotypic score(IPS), tumor prediction, tumor immune dysfunction and rejection(TIDE). RT-qPCR was used to determine the mRNA level of disulfidptosis prognostic gene. Risk groups was identified as potential predictors of immune cell infiltration, drug sensitivity, and immunotherapy responsiveness. HRG may benefit from immunotherapy. Classification is very effective in predicting the prognosis and therapeutic effect of patients, and provides a reference for accurate individualized treatment. This study suggests that new biomarkers related to Disulfidptosis can be used in clinical diagnosis of liver cancer to predict prognosis and treatment targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Anhui No.2 Provincial People's Hospital, Hefei 230000, China
- Anhui Medical University, Hefei 230000, China
- Anhui No.2 Provincial People's Hospital affiliated to Anhui Medical University, Hefei 230000, China
- The Fifth Clinical Medical College of Anhui Medical University, Hefei 230000, China
- Department of General Surgery, First affiliated Hospital of Anhui Medical University, Hefei 230000, China
Förderung
- Anhui Science and Technology Department
Zitieren
APA
Wang, T., Guo, K., Zhang, D., Wang, H., Yin, J., Cui, H., & Wu, W. (2023). Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile. International Immunopharmacology, 120, 110368. https://doi.org/10.1016/j.intimp.2023.110368
Vancouver
Wang T, Guo K, Zhang D, Wang H, Yin J, Cui H, et al. Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile. International Immunopharmacology. 2023;120:110368. doi:10.1016/j.intimp.2023.110368
BibTeX
@article{Wang2023,
author = {Wang, Tianbing and Guo, Kai and Zhang, Di and Wang, Haibo and Yin, Jimin and Cui, Haodong and Wu, Wenyong},
title = {Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile},
journal = {International Immunopharmacology},
year = {2023},
volume = {120},
pages = {110368},
doi = {10.1016/j.intimp.2023.110368}
}
EUVIMED